Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 5/2018

01-11-2018 | Original Article

Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre

Authors: Michael Moloney, David Faulkner, Emma Link, Danny Rischin, Ben Solomon, Annette M. Lim, John R. Zalcberg, Michael Jefford, Michael Michael

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2018

Login to get access

Abstract

Purpose

5-Fluorouracil (5FU) drug exposure correlates with treatment response and toxicity in cancer patients. Dosing is based upon body surface area which does not correlate with 5FU pharmacokinetics (PK)/pharmacodynamics. Therapeutic drug monitoring has enabled real-time 5FU dose adjustments: reducing toxicity with increased efficacy. The aim of this study was to assess feasibility of a 5FU monitoring service utilising a commercial kit in a quaternary cancer centre and to compare PK parameters to previously published studies.

Methods

Cancer patients receiving continuous infusional (CI) 5FU with ECOG PS 0–2, and adequate organ function, were eligible. Patients had blood samples taken at t = 0, mid infusion (if feasible) then 2 h pre infusion end. 5FU levels were measured using a commercial kit (My-5FU PCM™). A feasibility questionnaire was completed by trial nurses and toxicity data were recorded at baseline and at the commencement of the next cycle. 5FU pharmacokinetic exposure parameters were calculated.

Results

Twenty patients (12 male; 8 female), median age 62, (range 37–71) had samples taken. Twenty (100%) feasibility forms were available for assessment. Blood samples were taken at 51/69 (74%) specified time points. Ease of sample processing was recorded as easy in all 20 patients. Patient compliance with scheduled visits was 18/20 (90%). One form noted other difficulties with predicting end of infusion time. 19/20 patients had blood samples analysed. Mean measured 5FU AUC (0-Tlast) for 5FU 1 g/m2 with platinum: 35.8 h mg/L (range 28.56–44.26), mean Css 372.2 µg/L (range 297.5–461.0); 5FU 600 mg/m2 with platinum: 12.42 h mg/L (range 6.91–18.29), mean Css 111.0 µg/L (72.0–190.5) and 5FU 2400 mg/m2 as part of FOLFOX ± bevacizumab: 14.75 h mg/L (range 6.74–22.93), mean Css 320.70 µg/L (range 146.5–498.5). One patient had grade 4 neutropenia and one patient without PK parameters experienced febrile neutropenia (grade 4 neutropenia). Mucositis was observed in two patients: [5FU/platinum (1), grade 1, FOXFOX ± bevacizumab (1) grade 1]. Diarrhoea was reported in three patients [5FU/platinum (2) grade 1–2, FOXFOX ± bevacizumab (1) grade 1].

Conclusion

Therapeutic 5FU drug monitoring was feasible using commercial kits and analysers and hence warrants development as a routine standard of care in cancer patients. The variability in the 5FU exposure parameters is consistent with other studies using the My 5FU PCM kit.
Literature
1.
Dasmahapatra KS, Citrin P, Hill G, Yee R, Mohit-Tabatabai M, Rush B Jr (1985) A prospective evaluation of 5-fluorouracil plus cisplatin in advanced squamous-cell cancer of the head and neck. J Clin Oncol 3(11):1486–1489CrossRef
2.
Adelstein DJ (2003) Systemic chemotherapy for squamous cell head and neck cancer. Expert Opin Pharmacother 4(12):2151–2163CrossRef
3.
Adelstein DJ, LeBlanc M (2006) Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer? J Clin Oncol 24(17):2624–2628CrossRef
4.
Goldenberg D, Sciubba J, Koch WM (2006) Cystic metastasis from head and neck squamous cell cancer: a distinct disease variant? Head Neck 28(7):633–638CrossRef
5.
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359(11):1116–1127CrossRef
6.
Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P et al (1999) Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91(24):2081–2086CrossRef
7.
Poon MA, O’Connell MJ, Wieand HS, Krook JE, Gerstner JB, Tschetter LK et al (1991) Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9(11):1967–1972CrossRef
8.
de Gramont AD, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938–2947CrossRef
9.
Douillard J, Cunningham D, Roth A, Navarro M, James R, Karasek P et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355(9209):1041–1047CrossRef
10.
Baker SD, Verweij J, Rowinsky EK, Donehower RC, Schellens JH, Grochow LB et al (2002) Role of body surface area in dosing of investigational anticancer agents in adults, 1991–2001. J Natl Cancer Inst 94(24):1883–1888CrossRef
11.
Fety R, Rolland F, Barberi-Heyob M, Hardouin A, Campion L, Conroy T et al (1998) Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res 4(9):2039–2045PubMed
12.
Undevia SD, Gomez-Abuin G, Ratain MJ (2005) Pharmacokinetic variability of anticancer agents. Nat Rev Cancer 5(6):447–458CrossRef
13.
Gurney H (1996) Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 14(9):2590–2611CrossRef
14.
Felici A, Verweij J, Sparreboom A (2002) Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer 38(13):1677–1684CrossRef
15.
Meta-Analysis Group In C, Levy E, Piedbois P, Buyse M, Pignon JP, Rougier P et al (1998) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 16(11):3537–3541CrossRef
16.
Harris BE, Song R, Soong SJ, Diasio RB (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50(1):197–201PubMed
17.
Jacobs BA, Deenen MJ, Pluim D, van Hasselt JG, Krahenbuhl MD, van Geel RM et al (2016) Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers. Br J Clin Pharmacol 82(3):706–716CrossRef
18.
19.
Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U et al (2015) Clinical relevance of DPYD variants c.1679T > G, c.1236G > A/HapB3, and c.1601G > A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol 16(16):1639–1650CrossRef
20.
Harris BE, Carpenter JT, Diasio RB (1991) Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer 68(3):499–501CrossRef
21.
Diasio RB, Beavers TL, Carpenter JT (1988) Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 81(1):47–51CrossRef
22.
Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H et al (2016) Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol 34(3):227–234CrossRef
23.
van Kuilenburg AB (2004) Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40(7):939–950CrossRef
24.
van Kuilenburg AB, Haasjes J, Richel DJ, Zoetekouw L, Van Lenthe H, De Abreu RA et al (2000) Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 6(12):4705–4712PubMed
25.
Di Paolo A, Danesi R, Falcone A, Cionini L, Vannozzi F, Masi G et al (2001) Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann Oncol 12(9):1301–1306CrossRef
26.
Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH (2002) Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14 + 1g > a mutation. Int J Cancer 101(3):253–258CrossRef
27.
Saif MW, Choma A, Salamone SJ, Chu E (2009) Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst 101(22):1543–1552CrossRef
28.
Au JL-S, Rustum YM, Ledesma E, Mittelman A, Creaven PJ (1982) Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas. Cancer Res 42(7):2930–2937PubMed
29.
van Groeningen CJ, Pinedo HM, Heddes J, Kok RM, de Jong AP, Wattel E et al (1988) Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res 48(23):6956–6961PubMed
30.
Yoshida T, Araki E, Iigo M, Fujii T, Yoshino M, Shimada Y et al (1990) Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer. Cancer Chemother Pharmacol 26(5):352–354CrossRef
31.
Trump DL, Egorin MJ, Forrest A, Willson J, Remick S, Tutsch KD (1991) Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-h continuous infusion with and without dipyridamole. J Clin Oncol 9(11):2027–2035CrossRef
32.
Gamelin E, Boisdron-Celle M, Delva R, Regimbeau C, Cailleux P, Alleaume C et al (1998) Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol 16(4):1470–1478CrossRef
33.
Ychou M, Duffour J, Pinguet F, Kramar A, Joulia J, Topart D et al (1998) Individual 5FU-dose adaptation schedule using bimonthly pharmacokinetically modulated LV5FU2 regimen: a feasibility study in patients with advanced colorectal cancer. Anticancer Res 19(3B):2229–2235
34.
Ychou M, Duffour J, Kramar A, Debrigode C, Gourgou S, Bressolle F et al (2003) Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. Cancer Chemother Pharmacol 52(4):282–290CrossRef
35.
Hillcoat B, McCulloch P, Figueredo A, Ehsan MH, Rosenfeld J (1978) Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion. Br J Cancer 38(6):719CrossRef
36.
Di Paolo A, Lencioni M, Amatori F, Di Donato S, Bocci G, Orlandini C et al (2008) 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. Clin Cancer Res 14(9):2749–2755CrossRef
37.
Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D et al (2008) Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 26(13):2099–2105CrossRef
38.
Capitain O, Asevoaia A, Boisdron-Celle M, Poirier A-L, Morel A, Gamelin E (2012) Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. Clin Colorectal Cancer 11(4):263–267CrossRef
39.
Kline CLB, Schiccitano A, Zhu J, Beachler C, Sheikh H, Harvey HA et al (2014) Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early-or late-stage colorectal cancer patients treated with infusional 5-Fluorouracil-based chemotherapy regimens. Clin Colorectal Cancer 13(2):119–126CrossRef
40.
Saam J, Critchfield GC, Hamilton SA, Roa BB, Wenstrup RJ, Kaldate RR (2011) Body surface area-based dosing of 5-Fluoruracil results in extensive interindividual variability in 5-Fluorouracil exposure in colorectal cancer patients on FOLFOX regimens. Clin Colorectal Cancer 10(3):203–206CrossRef
41.
Denda T, Kanda M, Morita Y, Kim HM, Kashiwada T, Matsuda C et al (2016) Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial. Cancer Chemother Pharmacol 78(6):1253–1261CrossRef
42.
Wilhelm M, Mueller L, Miller MC, Link K, Holdenrieder S, Bertsch T et al (2016) Prospective, multicenter study of 5-Fluorouracil therapeutic drug monitoring in metastatic colorectal cancer treated in routine clinical practice. Clin Colorectal Cancer 15(4):381–388CrossRef
43.
Goel G, Sehgal R, Meisner DJ, Sun M, Pasricha G, Chu E et al (2015) Therapeutic drug monitoring of 5-fluorouracil (5-FU) in the treatment of patients with colorectal cancer (CRC). J Clin Oncol 33(3 suppl):563CrossRef
44.
Braiteh FS, Salamone SJ, Li Y, Courtney JB, Duda M, Diamond S et al (2014) Pharmacokinetic (PK)-guided optimization of 5-fluorouracil (5FU) exposure in colorectal cancer (CRC) patients: US-based clinical practices experience. J Clin Oncol 32(15 suppl):3574
45.
Patel JN, O’Neil BH, Deal AM, Ibrahim JG, Sherrill GB, Olajide OA et al (2014) A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy. Oncologist 19(9):959–965CrossRef
46.
Michael M, Gibbs P, Smith R, Godwood A, Oliver S, Tebbutt N (2009) Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer. Investig New Drugs 27(3):253–261CrossRef
47.
Michael M, Zalcberg J, Gibbs P, Lipton L, Gouillou M, Jefford M et al (2013) A phase I trial of imatinib in combination with mFOLFOX6–bevacizumab in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 71(2):321–330CrossRef
48.
Thyss A, Milano G, Renée N, Vallicioni J, Schneider M, Demard F (1986) Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother Pharmacol 16(1):64–66CrossRef
49.
Santini J, Milano G, Thyss A, Renee N, Viens P, Ayela P et al (1989) 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 59(2):287CrossRef
50.
Zahnd D, Aebi S, Rusterholz S, Fey M, Borner M (1999) A randomized crossover trial assessing patient preference for two different types of portable infusion-pump devices. Ann Oncol 10(6):727–729CrossRef
51.
Ilfeld BM, Morey TE, Enneking FK (2003) Delivery rate accuracy of portable, bolus-capable infusion pumps used for patient-controlled continuous regional analgesia. Reg Anesth Pain Med 28(1):17–23CrossRef
52.
Kaye T (1994) Prolonged infusion times with disponible elastomeric, infusion devices. AJHP Am J Hosp Pharm 51(4):533–534PubMed
53.
Veal DF, Altman CE, McKinnon BT, Fillingim O (1995) Evaluation of flow rates for six disposable infusion devices. Am J Health Syst Pharm 52(5):500–504PubMed
54.
Ackermann M, Maier S, Ing H, Bonnabry P (2007) Evaluation of the design and reliability of three elastomeric and one mechanical infusers. J Oncol Pharm Practice 13(2):77–84CrossRef
55.
LeReiger MBT, Martin D, Bessesworth J, Tobias JD (2014) Comparison of flow rate accuracy and consistency between the on-Q, baxter, and ambu pain devices. World J Anesthesiol 3(1):119–123CrossRef
56.
Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, Maillart PJ, Goudier M, Burtin PC et al (1996) Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 77(3):441–451CrossRef
57.
Diasio RB, Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16(4):215–237CrossRef
58.
Blaschke M, Cameron S, Emami K, Blumberg J, Wegner U, Nischwitz M et al (2011) Measurement of 5-FU plasma levels in patients with advanced cancer: correct approach to practical procedures is essential. Int J Clin Pharmacol Ther 49(1):83PubMed
59.
van Kuilenburg AB, Hausler P, Schalhorn A, Tanck MW, Proost JH, Terborg C et al (2012) Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905 + 1G > A mutation in DPYD by means of a Bayesian limited sampling strategy. Clin Pharmacokinet 51(3):163–174CrossRef
60.
Freeman K, Connock M, Cummins E, Gurung T, Taylor-Phillips S, Court R et al (2015) Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion. Health Technol Assess (Winch Engl) 19(91):1CrossRef
61.
ClinicalTrials.gov Study comparing optimized 5-FU dosing and standard dosing in metastatic colorectal cancer patients treated with FOLFOX6 (PROFUSE)
62.
Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):303–312CrossRef
Metadata
Title
Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre
Authors
Michael Moloney
David Faulkner
Emma Link
Danny Rischin
Ben Solomon
Annette M. Lim
John R. Zalcberg
Michael Jefford
Michael Michael
Publication date
01-11-2018
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2018
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-018-3679-4

Other articles of this Issue 5/2018

Cancer Chemotherapy and Pharmacology 5/2018 Go to the issue

Original Article

Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood

Original Article

Biotransformation of [14C]-ixazomib in patients with advanced solid tumors: characterization of metabolite profiles in plasma, urine, and feces

Original Article

Prognostic significance of CEACAM5mRNA-positive circulating tumor cells in patients with metastatic colorectal cancer

Short Communication

A comparison of the quality of informed consent for phase I oncology trials over a 30-year period

Original Article

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors

Review Article

Liposomal therapies in oncology: does one size fit all?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits